Conservative management of uterine pediatric rhabdomyosarcoma: A report from the intergroup rhabdomyosarcoma study III and IV pilot

Cynthia A. Corpron, Richard J. Andrassy, Daniel M. Hays, R. Beverly Raney, Eugene S. Wiener, Walter Lawrence, Thom E. Lobe, Harold M. Maurer

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Previous studies have suggested that women with uterine rhabdomyosarcomas (RMS) represent a distinct group of patients who present at an older age, are less responsive to treatment, and have a poorer prognosis than patients with vaginal RMS. During the Intergroup Rhabdomyosarcoma Study (IRS) III and the IRS IV pilot study, 14 patients were registered with uterine primary RMS. Three patients presented with cervical tumors that were completely removed (group 1). Eight patients had initial biopsies with gross residual disease (group 3), and 3 had metastatic disease at presentation (group 4). Of the 5 patients treated with primary chemotherapy or chemotherapy and radiation, 2 had delayed hysterectomy and vaginectomy, 1 had no further surgery, and 2 had exploratory laparotomy with no evidence of disease. There were no relapses or deaths in this group. One patient underwent initial resection of a broad ligament mass, experienced an early (3-week) recurrence of the mass while on chemotherapy, and progressed to developing distant metastases and death. Four patients died of chemotherapy toxicity or sepsis, one after achieving a complete response from chemotherapy and hysterectomy. This primary chemotherapy or chemotherapy and radiotherapy regimen resulted in 8 of 9 (89%) patients (not including those who died of chemotoxicity) surviving between 1.5 and 6 years without evidence of disease. Of the surviving patients, 2 had hysterectomy and vaginectomy, but pathological specimens showed only localized microscopic residual tumor. This report suggests that less vigorous operative resection may be possible in combination with primary chemotherapy when treating uterine rhabdomyosarcomas. However, evaluation of the excellent response to chemotherapy must include consideration of the 4 patients who died of sepsis or treatment complications.

Original languageEnglish (US)
Pages (from-to)942-944
Number of pages3
JournalJournal of pediatric surgery
Volume30
Issue number7
DOIs
StatePublished - Jul 1995

Fingerprint

Rhabdomyosarcoma
Pediatrics
Drug Therapy
Hysterectomy
Sepsis
Conservative Treatment
Broad Ligament
Recurrence
Residual Neoplasm
Laparotomy
Radiotherapy
Radiation
Neoplasm Metastasis
Biopsy

Keywords

  • Rhabdomyosarcoma
  • pediatric
  • uterine

ASJC Scopus subject areas

  • Surgery
  • Pediatrics, Perinatology, and Child Health

Cite this

Conservative management of uterine pediatric rhabdomyosarcoma : A report from the intergroup rhabdomyosarcoma study III and IV pilot. / Corpron, Cynthia A.; Andrassy, Richard J.; Hays, Daniel M.; Raney, R. Beverly; Wiener, Eugene S.; Lawrence, Walter; Lobe, Thom E.; Maurer, Harold M.

In: Journal of pediatric surgery, Vol. 30, No. 7, 07.1995, p. 942-944.

Research output: Contribution to journalArticle

Corpron, CA, Andrassy, RJ, Hays, DM, Raney, RB, Wiener, ES, Lawrence, W, Lobe, TE & Maurer, HM 1995, 'Conservative management of uterine pediatric rhabdomyosarcoma: A report from the intergroup rhabdomyosarcoma study III and IV pilot', Journal of pediatric surgery, vol. 30, no. 7, pp. 942-944. https://doi.org/10.1016/0022-3468(95)90317-8
Corpron, Cynthia A. ; Andrassy, Richard J. ; Hays, Daniel M. ; Raney, R. Beverly ; Wiener, Eugene S. ; Lawrence, Walter ; Lobe, Thom E. ; Maurer, Harold M. / Conservative management of uterine pediatric rhabdomyosarcoma : A report from the intergroup rhabdomyosarcoma study III and IV pilot. In: Journal of pediatric surgery. 1995 ; Vol. 30, No. 7. pp. 942-944.
@article{2efd1d021d7c42bcba4662e7fe1ecc37,
title = "Conservative management of uterine pediatric rhabdomyosarcoma: A report from the intergroup rhabdomyosarcoma study III and IV pilot",
abstract = "Previous studies have suggested that women with uterine rhabdomyosarcomas (RMS) represent a distinct group of patients who present at an older age, are less responsive to treatment, and have a poorer prognosis than patients with vaginal RMS. During the Intergroup Rhabdomyosarcoma Study (IRS) III and the IRS IV pilot study, 14 patients were registered with uterine primary RMS. Three patients presented with cervical tumors that were completely removed (group 1). Eight patients had initial biopsies with gross residual disease (group 3), and 3 had metastatic disease at presentation (group 4). Of the 5 patients treated with primary chemotherapy or chemotherapy and radiation, 2 had delayed hysterectomy and vaginectomy, 1 had no further surgery, and 2 had exploratory laparotomy with no evidence of disease. There were no relapses or deaths in this group. One patient underwent initial resection of a broad ligament mass, experienced an early (3-week) recurrence of the mass while on chemotherapy, and progressed to developing distant metastases and death. Four patients died of chemotherapy toxicity or sepsis, one after achieving a complete response from chemotherapy and hysterectomy. This primary chemotherapy or chemotherapy and radiotherapy regimen resulted in 8 of 9 (89{\%}) patients (not including those who died of chemotoxicity) surviving between 1.5 and 6 years without evidence of disease. Of the surviving patients, 2 had hysterectomy and vaginectomy, but pathological specimens showed only localized microscopic residual tumor. This report suggests that less vigorous operative resection may be possible in combination with primary chemotherapy when treating uterine rhabdomyosarcomas. However, evaluation of the excellent response to chemotherapy must include consideration of the 4 patients who died of sepsis or treatment complications.",
keywords = "Rhabdomyosarcoma, pediatric, uterine",
author = "Corpron, {Cynthia A.} and Andrassy, {Richard J.} and Hays, {Daniel M.} and Raney, {R. Beverly} and Wiener, {Eugene S.} and Walter Lawrence and Lobe, {Thom E.} and Maurer, {Harold M.}",
year = "1995",
month = "7",
doi = "10.1016/0022-3468(95)90317-8",
language = "English (US)",
volume = "30",
pages = "942--944",
journal = "Journal of Pediatric Surgery",
issn = "0022-3468",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - Conservative management of uterine pediatric rhabdomyosarcoma

T2 - A report from the intergroup rhabdomyosarcoma study III and IV pilot

AU - Corpron, Cynthia A.

AU - Andrassy, Richard J.

AU - Hays, Daniel M.

AU - Raney, R. Beverly

AU - Wiener, Eugene S.

AU - Lawrence, Walter

AU - Lobe, Thom E.

AU - Maurer, Harold M.

PY - 1995/7

Y1 - 1995/7

N2 - Previous studies have suggested that women with uterine rhabdomyosarcomas (RMS) represent a distinct group of patients who present at an older age, are less responsive to treatment, and have a poorer prognosis than patients with vaginal RMS. During the Intergroup Rhabdomyosarcoma Study (IRS) III and the IRS IV pilot study, 14 patients were registered with uterine primary RMS. Three patients presented with cervical tumors that were completely removed (group 1). Eight patients had initial biopsies with gross residual disease (group 3), and 3 had metastatic disease at presentation (group 4). Of the 5 patients treated with primary chemotherapy or chemotherapy and radiation, 2 had delayed hysterectomy and vaginectomy, 1 had no further surgery, and 2 had exploratory laparotomy with no evidence of disease. There were no relapses or deaths in this group. One patient underwent initial resection of a broad ligament mass, experienced an early (3-week) recurrence of the mass while on chemotherapy, and progressed to developing distant metastases and death. Four patients died of chemotherapy toxicity or sepsis, one after achieving a complete response from chemotherapy and hysterectomy. This primary chemotherapy or chemotherapy and radiotherapy regimen resulted in 8 of 9 (89%) patients (not including those who died of chemotoxicity) surviving between 1.5 and 6 years without evidence of disease. Of the surviving patients, 2 had hysterectomy and vaginectomy, but pathological specimens showed only localized microscopic residual tumor. This report suggests that less vigorous operative resection may be possible in combination with primary chemotherapy when treating uterine rhabdomyosarcomas. However, evaluation of the excellent response to chemotherapy must include consideration of the 4 patients who died of sepsis or treatment complications.

AB - Previous studies have suggested that women with uterine rhabdomyosarcomas (RMS) represent a distinct group of patients who present at an older age, are less responsive to treatment, and have a poorer prognosis than patients with vaginal RMS. During the Intergroup Rhabdomyosarcoma Study (IRS) III and the IRS IV pilot study, 14 patients were registered with uterine primary RMS. Three patients presented with cervical tumors that were completely removed (group 1). Eight patients had initial biopsies with gross residual disease (group 3), and 3 had metastatic disease at presentation (group 4). Of the 5 patients treated with primary chemotherapy or chemotherapy and radiation, 2 had delayed hysterectomy and vaginectomy, 1 had no further surgery, and 2 had exploratory laparotomy with no evidence of disease. There were no relapses or deaths in this group. One patient underwent initial resection of a broad ligament mass, experienced an early (3-week) recurrence of the mass while on chemotherapy, and progressed to developing distant metastases and death. Four patients died of chemotherapy toxicity or sepsis, one after achieving a complete response from chemotherapy and hysterectomy. This primary chemotherapy or chemotherapy and radiotherapy regimen resulted in 8 of 9 (89%) patients (not including those who died of chemotoxicity) surviving between 1.5 and 6 years without evidence of disease. Of the surviving patients, 2 had hysterectomy and vaginectomy, but pathological specimens showed only localized microscopic residual tumor. This report suggests that less vigorous operative resection may be possible in combination with primary chemotherapy when treating uterine rhabdomyosarcomas. However, evaluation of the excellent response to chemotherapy must include consideration of the 4 patients who died of sepsis or treatment complications.

KW - Rhabdomyosarcoma

KW - pediatric

KW - uterine

UR - http://www.scopus.com/inward/record.url?scp=0029143134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029143134&partnerID=8YFLogxK

U2 - 10.1016/0022-3468(95)90317-8

DO - 10.1016/0022-3468(95)90317-8

M3 - Article

C2 - 7472949

AN - SCOPUS:0029143134

VL - 30

SP - 942

EP - 944

JO - Journal of Pediatric Surgery

JF - Journal of Pediatric Surgery

SN - 0022-3468

IS - 7

ER -